Glucagon formulations comprising a low viscosity mixture of: i) at least one diacylglycerol ii) at least one phospholipid iii) at least one glucagon iv) at least one biocompatible organic solvent v) optionally at least one lipid soluble acid and vi) optionally at least one antioxidant, wherein the pre-formulation generates at least one bulk non-lamellar phase structure upon exposure to excess aqueous fluid are useful in preventing hypoglycemia, particularly in diabetic subjects receiving insulin therapy, and to pre-filled administration devices and kits containing the formulations.
